An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy
Clinical trial NCT07238868 · RECRUITING
Trial details
- NCT number
- NCT07238868
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-14
- Primary completion
- 2029-01-01
- Enrollment
- 144
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.